Answer
Linagliptin in Glyxambi inhibits DPP-4, increasing and prolonging active GLP-1 and GIP incretin levels, which increase insulin secretion and reduce glucagon secretion in a glucose-dependent manner, thereby reducing liver glucose production and lowering blood glucose.
Sources for this answer
- Glyxambi 10 mg/5 mg film-coated tablets and Glyxambi 25 mg/5 mg film-coated tabletsBoehringer Ingelheim Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 14Document updated
Sources checked